Søgeresultater - Jason A Clark
- Showing 1 - 4 results of 4
-
1
-
2
-
3
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis af John Mascarenhas, Moshe Talpaz, Vikas Gupta, Lynda Foltz, Michael R. Savona, Ronald Paquette, A. Robert Turner, Paul Coughlin, Elliott F. Winton, Timothy C. Burn, Peter O’Neill, Jason A. Clark, Deborah Hunter, Albert Assad, Ronald Hoffman, Srđan Verstovšek
Udgivet 2016Artigo -
4
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors af Elizabeth J. Davis, Juan Martín-Liberal, Rebecca Kristeleit, Daniel C. Cho, Sarah P. Blagden, Dominik Berthold, Dana B. Cardin, María Vieito, Rowan Miller, Prashanth Hari Dass, Angela Orcurto, Kristen Spencer, John E. Janik, Jason A. Clark, Thomas Condamine, Jennifer Pulini, Xuejun Chen, Janice M. Mehnert
Udgivet 2022Artigo
Søgeredskaber:
Relaterede emner
Medicine
Internal medicine
Biology
Cancer
Gene
Genetics
Oncology
Adverse effect
Axilla
Bone marrow
Breast cancer
CLOCK
Cell biology
Circadian clock
Circadian rhythm
Clinical trial
Dermatology
Disease
Endocrinology
Gastroenterology
Genetic heterogeneity
Hedgehog signaling pathway
Immunotherapy
Inheritance (genetic algorithm)
Intertriginous
Keloid
Melatonin
Myelofibrosis
Open label
PER1